Previous Article | Next Article 
Journal of Clinical Microbiology, November 1998, p. 3243-3247, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Detection of Active Infection in Nonhuman Primates
with Lyme Neuroborreliosis: Comparison of PCR, Culture, and
a Bioassay
Andrew R.
Pachner,1,*
Wei-Fen
Zhang,1
Henry
Schaefer,1
Susan
Schaefer,1 and
Tim
O'Neill2
Department of Neurology, Georgetown
University School of Medicine,1 and
Comparative Registry of Pathology, Armed Forces Institute
of Pathology,2 Washington, D.C.
Received 15 May 1998/Returned for modification 9 July 1998/Accepted 4 August 1998
 |
ABSTRACT |
Ideally a diagnosis of infection of the central nervous system
(CNS) is made by culture of the etiologic pathogen, but Borrelia burgdorferi, the causative agent of Lyme neuroborreliosis (LNB), is rarely cultured from the cerebrospinal fluid (CSF). PCR and measurement of specific antibody in the CSF also have their
limitations. The role of available assays for LNB has not been studied
carefully in a comparative investigation. There is a need to assess the reliability of assays and to increase the ability to document active
infection in the CNS. The recent development of the nonhuman primate
(NHP) model of LNB allowed us to address this need in a faithful model
of human LNB. In this study we compared the abilities of PCR and
culture to detect the presence of spirochetes in the CSF and brain
tissue of infected NHPs and related these measures of infection to the
development of anti-B. burgdorferi antibody. We also
tested a bioassay, the mouse infectivity test (MIT), in this model.
Fourteen of 16 CSFs from four NHPs were positive by at least one of
these techniques. Detection of spirochetes in the CSF by PCR, the MIT,
and culture was inversely related to the concomitant presence of
anti-B. burgdorferi antibody intrathecally. The
performance of any particular test was associated with the strength of
the host immune response. In early CNS infection, when
anti-B. burgdorferi antibody had not yet appeared, or
in immunocompromised hosts, the MIT compared favorably to culture and
PCR for infected NHPs; antibody in the CSF was the most useful assay
for immunocompetent NHPs.
 |
INTRODUCTION |
The diagnosis of Lyme
neuroborreliosis (LNB) can frequently be made by
characteristic clinical findings (18). Positive
serologies in the serum or cerebrospinal fluid (CSF) are helpful to
confirm the diagnosis. However, neurological involvement can have
protean clinical manifestations (7), and the appearance of
antibody in the serum or CSF may be delayed for many weeks to months
after infection. Ideally, the causative organism, Borrelia
burgdorferi, would be cultured from the CSF, but the spirochete is
highly fastidious, and culture has poor diagnostic sensitivity
(4). PCR assays have aided diagnosis but have a high
incidence of false negativity (6, 10). Thus, there is a need
for additional tests to improve detection of the spirochete in CSF and
neurological tissue in LNB.
The recent development of the nonhuman primate (NHP) model (11,
12, 19), which is the only faithful model of LNB (1), has set the stage for answering many questions about LNB and has raised
the possibility of developing diagnostic assays which may have utility
in human LNB.
Transfer of infection from human CSF to experimental animals is
considered to be the "gold standard" for the related spirochetal infection neurosyphilis (21, 24) and has been used to
confirm human relapsing fever. This technique has not been tested for LNB. Since the two infections are closely related, we hypothesized that transfer of infection from CSF or tissue to mice, i.e., the mouse
infectivity test (MIT), may be a useful adjunct in the
diagnosis of neuroborreliosis. We tested this hypothesis in NHP LNB and compared the ability of the MIT to detect the presence of the spirochete in CSF and tissues to those of PCR, culture, and
anti-B. burgdorferi antibody determination.
 |
MATERIALS AND METHODS |
NHPs and spirochetes.
The four adult rhesus macaques
(Macaca mulatta; two male and two female) used in this study
were housed, cared for, and anesthetized and underwent cisternal
punctures as previously described (12). This housing and
care was in accordance with the Animal Welfare Act and the Guide for
the Care and Use of Laboratory Animals (24a) in facilities
accredited by the American Association for Accreditation of Laboratory
Animal Care. Prior to initiation, the study was reviewed and approved
by the Georgetown University Animal Care and Use Committee.
Two NHPs, PAX219 (male) and Z1 (female), were treated orally with
dexamethasone (2 mg/kg of body weight/day for 1 week, then 1 mg/kg/day)
for 9.5 weeks after infection, a dosage considered low to moderate for
rhesus macaques; these NHPs will be referred to as
"immunocompromised." Two NHPs, Z23 and E680, did not receive dexamethasone and will be referred to as "immunocompetent." The immunocompromised NHPs were necropsied 9.5 weeks postinfection, after
euthanasia with ketamine, xylazine, and pentobarbital. The immunocompetent NHPs were necropsied at 13 weeks postinfection. Prior
to necropsy, the NHPs were perfused with 4 liters of normal salines.
The N40Br strain was used for intradermal inoculations as previously
described (12). This strain has been passaged through mouse
and NHP brains (12-14) and has resulted in central nervous system (CNS) invasion in all 21 NHPs tested thus far.
MIT.
CSF or tissue homogenate (0.1 ml) was injected
intradermally immediately after being obtained into each of two mice
per homogenate sample. The mice were given 0.25 µg of dexamethasone
on the day prior to infection and daily for the 2 weeks following to
delay the antibody response and allow a small inoculum to
establish infection. Six weeks after injection, i.e., 4 weeks after
completion of the dexamethasone treatment, the mice were bled and if
the enzyme-linked immunosorbent assays (ELISAs) or immunoblots were positive, the mice were sacrificed and the hearts were cultured. Mice
which were seronegative on the bleed at 6 weeks were retested at 12 weeks. The requirements for a positive MIT were all of the following:
(i) positive ELISAs for anti-B. burgdorferi
immunoglobulin G (IgG) antibodies in the sera of the recipient mice,
(ii) positive immunoblots (IgG) of the sera of the recipient mice, and
(iii) positive heart cultures of the recipient mice at sacrifice.
Culture and antibody measurement of mouse serum and NHP serum and
CSF.
A sample of CSF was analyzed immediately after withdrawal for
a cell count; no CSF had more than 1,000 erythrocytes/mm3.
The CSF and tissues were cultured as previously described
(12). Serum and CSF antibody studies were performed as
previously described (9, 12, 13). In brief, the antigens
used in the ELISAs and immunoblots were sonicates of the strain N40Br.
Two hundred microliters of antigen coating solution was added to each
well of a microtitration plate (Linbro Scientific, Hamden, Conn.) at a
concentration of 5 µg/ml and incubated overnight at 4°C. The plates
were washed three times with phosphate-buffered saline-0.05% Tween
20, and 200 µl of the sera was added at 1/500 dilution. The plates
were incubated for 2 h at 37°C and then washed again as
described above. Two hundred microliters of horseradish
peroxidase-conjugated goat anti-human (or anti-mouse for mouse serum)
immunoglobulin, isotypes G, A, and M (Organon Teknika-Cappel, Malvern,
Pa.), was diluted 1:10,000 in phosphate-buffered saline-Tween 20 and
added to each well. Incubation followed for 2 h at 37°C. The
plates were washed, and 200 µl of TMB microwell peroxidase substrate (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) was added to
each well, immediately after which 50 µl of 8% sulfuric acid was
added to stop the reaction. The plates were read immediately on an
ELISA spectrophotometer (Bio-Rad) at 450 nm. On each plate, a standard
positive control was run within its linear range of dilutions, and
plate-to-plate comparisons were adjusted on the basis of the readings
within the linear range of the positive controls on each plate. All
serum and CSF studies were performed in duplicate.
Immunoblotting of mouse and NHP sera was performed as previously
described (
12,
15), except that commercial
B. burgdorferi nitrocellulose strips (Microbiology Reference
Laboratory, Cypress,
Calif.) were used instead of strips made from
electrotransferred
sodium dodecyl sulfate-polyacrylamide gels. The
criteria for immunoblot
positivity were the same as those outlined by
the Centers for
Disease Control and Prevention-American Society of
Public Health
Laboratory Directors for IgG reactivity for human Lyme
disease,
a modification of those published by Dressler et al.
(
3): for
IgM, reactivity to at least two of the 23, 39, and
41 kDa proteins;
for IgG, reactivity to five or more of the 18, 21, 30, 39, 41,
45, 58, 66, and 93 kDa proteins.
PCR.
Analysis of tissue and CSF samples from the NHPs for
B. burgdorferi DNA was performed by PCR-ELISA, using
techniques previously described (8, 11, 12). Whole-blood DNA
was extracted as previously described (12). CSFs were boiled
prior to the PCR to inactivate proteinases. Minced tissues were treated
with proteinase K, extracted with phenol-chloroform, and precipitated
with ethanol. The ratios of the optical densities at 260 nm
(OD260s) and OD280s the extracted DNAs prior to
PCR were required to be 1.5 or greater; if they were less than 1.5, extraction was repeated. If after reextraction the ratio of the sample
was not greater than 1.5, the sample was not used and another frozen
block of tissue was processed.
All reagents were from the PCR-ELISA reagents provided by
Boehringer-Mannheim (Indianapolis, Ind.) unless otherwise stated.
Five
hundred nanograms of tissue DNA was then used as a template;
digoxigenin-11-UTP (0.01 M) was one of the nucleotides added to
the PCR
mixture. Both OspA (
20) and OspB PCR-ELISAs were run
separately on all specimens, and the specimens were considered
positive
only if both PCRs were positive.
The PCR product was subjected to hybridization with the appropriate
biotinylated probe (biotinylation was performed at Lofstrand
Laboratories, Gaithersburg, Md.) and subsequently captured on
a
streptavidin-coated plate. The PCR product bound on the plate
was
detected by addition of an anti-digoxigenin antibody conjugated
to
alkaline phosphatase with subsequent color development with
substrate.
NHP brain and heart tissue from uninfected animals
served as negative
controls, and previously positive DNA and plasmid
DNA containing the
target served as positive controls. The OD
reading of the ELISA plate,
which served as a cutoff for positivity,
was the mean plus 4 standard
deviations of the negative controls.
The following probes and primers for the two
B. burgdorferi genes (the OspA and OspB genes) were used in the
PCR-ELISA: OspA149
(5'-TTATGAAAAAATATTTATTGGGAAT), OspA319
(5'-CTTTAAGCTCAAGCTTGTCTACTGT),
and the probe OspAwt3
(5'-AGCGTTTCAGTAGATTTGCCTGCTGGTG) and OspB-1110
(5'-AAACGCTAAACAAGACCTTCCTG), OspB-1411
(5'-AGCTTTGAGAGTTTCCTCTGTTATTGA),
and the probe
5'-TGAGGCTTTGAACCTTCAAGGGTTCCAGAACC.
 |
RESULTS |
CSF and serum.
The MIT, culture, PCR, and antibody studies of
the CSF obtained at the time of inoculation prior to infection
were negative in all four animals. A previous study (12) had
documented the fact that CNS invasion did not occur prior to 3 weeks
after inoculation in NHP LNB; thus, the earliest cisternal tap was done
3.5 weeks after infection. Table 1 shows
the data on the CSFs at 3.5 weeks and later for the four NHPs. For CSFs
obtained 3.5 weeks or more after inoculation, one or more of the four
assays were positive for 14 of 16 CSF specimens.
For seven of eight specimens from the immunocompromised NHPs, one or
more tests of infection were positive (Table
1). For
four of eight CSFs
obtained after the baseline studies of the
immunocompromised NHPs, the
MIT was positive. This compared favorably
to 3 of 8 culture positivity
and 4 of 8 PCR positivity. The MIT
was the only test positive in 2 of 8 CSF samples from the immunocompromised
NHPs.
CSF antibody measured by ELISA was negative in all CSF specimens from
immunocompromised NHPs (Fig.
1), despite
a low level
of specific antibody that appeared in the blood by week 3.5 and
steadily rose by the time of necropsy at week 9.5 (Fig.
2). None
of the CSFs from the
immunocompromised NHPs had a lymphocytic
pleocytosis. Serum immunoblot
was negative at week 3.5, positive
for only IgM at week 5.5, and
negative thereafter. Although sera
from the immunocompromised NHPs had
a number of
B. burgdorferi-specific
and nonspecific IgG
bands on immunoblots, none of the samples
met the criteria for
positivity, i.e., having five or more
B. burgdorferi-specific bands. Since current Centers for Disease
Control and Prevention criteria for positive Lyme serologies require
immunoblot positivity, none of these NHPs seroconverted, according
to
this definition.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
CSF anti-B. burgdorferi antibody levels
as a function of time postinoculation (p.i.). OD is presented as raw
data, e.g., the OD when saline was used as the antibody source was 0.2 to 0.25. Serum was tested at a dilution of 1:500.
|
|

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 2.
Serum anti-B. burgdorferi antibody
levels as a function of time postinoculation (p.i.). OD is presented as
raw data, e.g., the OD when saline was used as the antibody source was
0.2 to 0.25. CSF was tested at a dilution of 1:10.
|
|
In the CSFs obtained from immunocompetent NHPs, specific antibody was
detectable by 5.5 weeks after inoculation (Fig.
1).
CSF pleocytosis, a
leukocyte count above 5/mm
3, was present in samples from
week 5.5 in E680 and weeks 5.5 and
7.5 in Z23. Serum antibody levels
were much higher in the two
immunocompetent NHPs, as shown for 1:500
dilutions of sera in
Fig.
2; this dilution of the sera was chosen to
demonstrate the
very slow development of serum antibody in the
immunocompromised
NHPs. When higher dilutions of sera were used the
differences
between the two groups in the ODs of the week 7.5 and 9.5 sera
were even more striking. Sera were immunoblot positive for both
IgM and IgG at the week 3.5 analysis. The sera from these NHPs
remained
IgG immunoblot positive, but the IgM response became
negative in both
animals after week 5.5.
Blood PCR and culture were negative in all NHPs tested except for the
blood PCR from PAX219, which was positive on the week
3.5 blood draw.
No animal developed any clinically evident disease,
which was
consistent with our previous study (
12).
Tissue.
The MIT outperformed culture in samples from the CNSs
of the immunocompromised NHPs in that culture of the CNS was negative for all five specimens tested while the MIT was positive for two of
these specimens (Table 2). The MIT and
PCR were concordant for five of the six tissue samples. The MIT was
positive for one sample which was negative by both of the other
studies, i.e., the pons from PAX219, and PCR was positive for one
sample which was negative by both of the other studies, i.e., the
medulla from PAX 219.
PCR was performed on an additional 18 CNS specimens, 5 peripheral
nervous system tissues, and 6 extraneural organs from the
two
immunocompromised NHPs

tissues not tested by the MIT. PCR
with both
targets in these tissues was positive in nine, five,
and six of these
areas, respectively. The CNS localization was
primarily in subtentorial
structures, as reported for previous
NHPs infected with N40Br
(
11). Culture was positive for only
1 of 13 of the CNS
tissues from the immunocompromised NHPs, a
thoracic spinal cord sample
from PAX 219. The only positive culture
of tissue from Z1 was a
heart sample. Findings on PCR with the
OspA gene target were
confirmed by the second PCR assay with the
OspB gene target for all CSF
and tissue specimens tested.
The MIT and culture were negative for all six tissues sampled from the
immunocompetent NHPs. The yield of detection of
B. burgdorferi in tissue at necropsy was lower for these NHPs than
for the immunocompromised group, with 5 of 21 CNS tissues, 3 of
7 peripheral nervous system tissues, and 3 of 9 extraneural organs
positive.
 |
DISCUSSION |
The diagnosis of human LNB can be difficult. Its major
clinical manifestations
meningitis, facial palsy, radiculitis,
and neuritis
are nonspecific. In this infection, as in other bacterial infections of the CNS, culture of the causative agent from the CSF
would be the most useful diagnostic assay. Positive cultures from
patients with Lyme neuroborreliosis have been reported (4, 17), and there were positive cultures of some CSFs in this study, but generally culture has too low a yield to be relied upon
exclusively. In both human and NHP Lyme neuroborreliosis (4,
12), culture positivity of the CSF occurs relatively early
after CNS invasion, prior to the development of a significant
intrathecal antibody response.
PCR of the CSF has also been able to identify spirochete DNA in
clinical specimens. The sensitivity of this assay is much higher than
that of culture in patients with Lyme meningitis, with positive assays
in up to 40% of patients with early Lyme meningitis (5, 6,
10). However, CSF PCR suffers from a number of disadvantages: it
is not standardized, it is expensive, contamination can be a common
cause of false positives in laboratories not ideally suited for
the technique, and it detects dead as well as live spirochetes.
The presence of specific anti-B. burgdorferi antibody
in the CSF is the most widely used assay for Lyme neuroborreliosis. In
the immunocompetent NHPs in our study it was a very successful assay for detection of CNS invasion. However, it is frequently false
negative, especially early in the course of the infection or if there
is transient immunosuppression. Transient suppression of the
anti-B. burgdorferi immune response in humans could
occur in instances of coinfection, i.e., simultaneous transmission via the tick of pathogen other than B. burgdorferi.
Coinfection of ixodid ticks has been demonstrated for a number of
pathogens, including the agent of human granulocytic ehrlichiosis
(16), babesiosis (25), and tick-borne
encephalitis virus, as well as for a newly described virus
(23) and bacterium (22). In a recent study from
an endemic area of New Jersey, 18% of infected ticks were infected
with more than one readily identifiable pathogen (25); this
number is likely an underestimate, since many tick-borne agents have
not yet been identified. Infections, even subclinical ones, with a
variety of pathogens have been demonstrated to suppress the expected
host immune response (2). Thus, mild immunosuppression as
accomplished in this study was designed to mimic conditions in the
human host which allow B. burgdorferi in the natural
state to gain a firm foothold in the CNS in the 10 to 15% of
B. burgdorferi-infected patients who develop
clinically symptomatic nervous system disease.
This study is the first to compare the utilities of available
diagnostic techniques for LNB in which necropsy proved the presence of
infection in the CNS. None of the assays was ideal for all conditions,
and the utility of an assay was associated with the host immune status.
The differences in the responses of immunocompromised and
immunocompetent NHPs in this study were striking. In immunocompetent NHPs the window of opportunity for CNS invasion prior to the
development of CSF antibody was brief, and the chance of detection of
spirochetes by any of the three techniques used (i.e., culture,
PCR, or the MIT) was low; in this group, measurement of CSF
antibody was generally diagnostic. In immunocompromised NHPs,
intrathecal antibody production was delayed, and this helpful
diagnostic assay was false negative; diagnosis required more
labor-intensive assays, such as PCR, culture, and the MIT, during weeks
3.5 to 9.5 after infection. It is likely that had the experiment been
allowed to proceed longer in the immunocompetent NHPs, antibody would
have eventually been produced intrathecally.
This is the first study demonstrating that a bioassay using inoculation
of mice, the MIT, has potential as a useful adjunct in the diagnosis of
LNB. The MIT for LNB was modeled after the rabbit infectivity
test, which is considered the "gold standard" for the diagnosis of
the related CNS infection neurosyphilis and which is felt to be very
sensitive and specific (21, 24). The clinical application of
the MIT to human LNB is unclear. The advantages are summarized
above and include direct demonstration of infection, especially in
situations where other tests are negative. The disadvantages are
similar to those described for the rabbit infectivity test for
neurosyphilis, i.e., the requirement for special facilities, expense,
and long delay in getting results after the spinal tap. Thus, it may
prove to be particularly useful as an adjunctive assay in academic
centers or in clinical or basic research studies of LNB.
The clinical relevance of the data on comparison of diagnostic assays
is clear. The appearance of anti-B. burgdorferi
antibody in the CSF may be delayed, especially when there is
interference with the anti-B. burgdorferi immune
response. In these circumstances, or for a short time early in
CNS invasion in immunocompetent individuals, the measurement of
anti-B. burgdorferi antibody in the CSF may be
negative; under these circumstances the likelihood of detecting spirochetes by PCR, culture, or the MIT is highest. Conversely, detecting the presence of spirochetes by culture, PCR, or the MIT will
be least likely to be successful when anti-B.
burgdorferi antibody is present.
This study measured anti-B. burgdorferi antibody as
both a diagnostic assay and an indicator of the host immune response
toward the spirochete and its suppression by the administration of the corticosteroid dexamethasone. This drug probably also interfered with
arms of the immune response other than the humoral arm. For instance,
we did not include measurement of cellular immune measures or
macrophage functions in our study. It is likely that these arms of the
immune response are also important in the response to B. burgdorferi.
Ideally, studies such as this of an infectious disease would be
performed either with humans or with subprimate models, such as
rodents or rabbits. Unfortunately, performing this study with humans
would be very difficult, and there are no adequate rodent or
rabbit models currently in use which mimic human LNB. The use of
the rhesus macaque model of LNB, which is highly faithful to the human
infection (1), allowed the confirmation of CNS infection by
necropsy studies, an impossible feat with humans in this infection readily treatable with antibiotics.
 |
ACKNOWLEDGMENTS |
This work was supported by the NIH (RO1-NS 34933) and by the
Comparative Registry of Pathology's support of T. O'Neill.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Neurology, Georgetown University Hospital, 3800 Reservoir Rd.,
Washington, DC 20007. Phone: (202) 687-8587. Fax: (202) 784-2261. E-mail: apachn01{at}gumedlib.georgetown.edu.
 |
REFERENCES |
| 1.
|
Coyle, P. K.
1995.
Neurological Lyme disease: is there a true animal model?
Ann. Neurol.
38:560-562[Medline].
|
| 2.
|
Dempsey, W. L.,
A. L. Smith, and P. S. Morahan.
1986.
Effect of inapparent murine hepatitis virus infections on macrophages and host resistance.
J. Leukoc. Biol.
39:559-565[Abstract].
|
| 3.
|
Dressler, F.,
J. A. Whalen,
B. N. Reinhardt, and A. C. Steere.
1993.
Western blotting in the serodiagnosis of Lyme disease.
J. Infect. Dis.
167:392-400[Medline].
|
| 4.
|
Karlsson, M.,
K. Hovind-Hougen,
B. Svenungsson, and G. Stiernstedt.
1990.
Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis.
J. Clin. Microbiol.
28:473-479[Abstract/Free Full Text].
|
| 5.
|
Lebech, A. M., and K. Hansen.
1992.
Detection of Borrelia burgdorferi DNA by polymerase chain reaction in urine and cerebrospinal fluid of patients with early and late Lyme neuroborreliosis.
J. Clin. Microbiol.
30:1646-1653[Abstract/Free Full Text].
|
| 6.
|
Nocton, J. J.,
B. J. Bloom,
B. J. Rutledge,
D. H. Persing,
E. L. Logigian,
C. H. Schmid, and A. C. Steere.
1996.
Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis.
J. Infect. Dis.
174:623-627[Medline].
|
| 7.
|
Pachner, A. R.
1988.
Borrelia burgdorferi in the nervous system: the new "Great Imitator."
Ann. N.Y. Acad. Sci.
539:56-64[Medline].
|
| 8.
|
Pachner, A. R.,
K. Amemiya,
E. Delaney,
T. O'Neill,
C. N. Hughes, and W.-F. Zhang.
1997.
Interleukin 6 is expressed at high levels in the CNS in Lyme neuroborreliosis.
Neurology
49:147-152[Abstract/Free Full Text].
|
| 9.
|
Pachner, A. R., and E. Delaney.
1993.
Murine Lyme borreliosis: route of inoculation determines immune response and infectivity.
Reg. Immunol.
4:345-351.
|
| 10.
|
Pachner, A. R., and E. Delaney.
1993.
The polymerase chain reaction (PCR) in the diagnosis of Lyme neuroborreliosis.
Ann. Neurol.
34:544-550[Medline].
|
| 11.
|
Pachner, A. R.,
E. Delaney, and T. O'Neill.
1995.
Neuroborreliosis in the non-human primates: Borrelia burgdorferi persists in the central nervous system.
Ann. Neurol.
38:667-679[Medline].
|
| 12.
|
Pachner, A. R.,
E. Delaney,
T. O'Neill, and E. Major.
1995.
Inoculation of non-human primates with the N40 strain of Borrelia burgdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease.
Neurology
45:165-172[Abstract/Free Full Text].
|
| 13.
|
Pachner, A. R., and A. Itano.
1990.
Borrelia burgdorferi infection of the brain: characterization of the organism and response to antibiotics and immune sera in the mouse model.
Neurology
40:1535-1540[Abstract/Free Full Text].
|
| 14.
|
Pachner, A. R.,
N. Ricalton, and E. Delaney.
1993.
Comparison of polymerase chain reaction with culture and serology in murine experimental Lyme borreliosis.
J. Clin. Microbiol.
31:208-214[Abstract/Free Full Text].
|
| 15.
|
Pachner, A. R., and N. S. Ricalton.
1992.
Western blotting in evaluating Lyme seropositivity and the utility of a gel densitometric approach.
Neurology
42:2185-2192[Abstract/Free Full Text].
|
| 16.
|
Pancholi, P.,
C. P. Kolbert,
P. D. Mitchell,
K. D. Reed,
J. S. Dumler,
J. S. Bakken,
S. R. Telford, and D. H. Persing.
1995.
Ixodes dammini as a potential vector of human granulocytic ehrlichiosis.
J. Infect. Dis.
172:1007-1012[Medline].
|
| 17.
|
Pfister, H. W.,
V. Preac-Mursic,
B. Wilske,
K. M. Einhaupl, and K. Weinberger.
1989.
Latent Lyme neuroborreliosis: presence of Borrelia burgdorferi in the cerebrospinal fluid without concurrent inflammatory signs.
Neurology
39:1118-1120[Abstract/Free Full Text].
|
| 18.
|
Reik, L.,
A. C. Steere,
N. H. Bartenhagen,
R. E. Shope, and S. E. Malawista.
1979.
Neurologic abnormalities of Lyme disease.
Medicine
58:281-294[Medline].
|
| 19.
|
Roberts, E. D.,
R. P. Bohm,
F. B. Cogswell,
H. N. Lanners,
R. C. Lowrie,
L. Povinelli,
J. Piesman, and M. T. Philipp.
1995.
Chronic Lyme disease in the rhesus monkey.
Lab. Investig.
72:146-160[Medline].
|
| 20.
|
Rys, P. N.
1993.
PCR detection of Borrelia burgdorferi, p. 203-210.
In
D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (ed.), Diagnostic molecular microbiology: principles and applications. American Society for Microbiology, Washington, D.C.
|
| 21.
|
Sanchez, P. J.,
G. D. Wendel,
E. Grimprel,
M. Goldberg,
M. Hall,
O. Arencibia-Mireles,
M. V. Norgard, and J. D. Radolf.
1993.
Evaluation of molecular methodologies and rabbit infectivity testing for the diagnosis of congenital syphilis and neonatal central nervous system invasion by Treponema pallidum.
J. Infect. Dis.
167:148-157[Medline].
|
| 22.
|
Schwarzova, K., and I. Ciznar.
1996.
Spirochetal non-Borrelia microorganisms isolated from Ixodes ricinus.
Folia Microbiol.
41:175-180.
|
| 23.
|
Telford, S. R.,
P. M. Armstrong,
P. Katavolos,
I. Foppa,
A. S. Garcia,
M. L. Wilson, and A. Spielman.
1997.
A new tick-borne encephalitis-like virus infecting New England deer ticks, Ixodes dammini.
Emerg. Infect. Dis.
3:165-170[Medline].
|
| 24.
|
Turner, T. B.,
P. H. Hardy, and B. Newman.
1969.
Infectivity tests in syphilis.
Br. J. Vener. Dis.
45:183-195[Medline].
|
| 24a.
|
U.S. Department of Health and Human Services.
1985.
Guide for the care and use of laboratory animals. Publication no. 85-23. U.S.
Department of Health and Human Services, Washington, D.C.
|
| 25.
|
Varde, S.,
J. Beckley, and I. Schwartz.
1998.
Prevalence of tick-borne pathogens in Ixodes scapularis in a rural New Jersey county.
Emerg. Infect. Dis.
4:97-99[Medline].
|
Journal of Clinical Microbiology, November 1998, p. 3243-3247, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pachner, A. R., Dail, D., Li, L., Gurey, L., Feng, S., Hodzic, E., Barthold, S.
(2002). Humoral Immune Response Associated with Lyme Borreliosis in Nonhuman Primates: Analysis by Immunoblotting and Enzyme-Linked Immunosorbent Assay with Sonicates or Recombinant Proteins. CVI
9: 1348-1355
[Abstract]
[Full Text]
-
Pachner, A. R., Amemiya, K., Bartlett, M., Schaefer, H., Reddy, K., Zhang, W.-F.
(2001). Lyme Borreliosis in Rhesus Macaques: Effects of Corticosteroids on Spirochetal Load and Isotype Switching of Anti-Borrelia burgdorferi Antibody. CVI
8: 225-232
[Abstract]
[Full Text]